A phase II trial of Imbruvica showed that more than 30 percent of treated relapsed/refractory mantle cell lymphoma patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Forty-seven percent of the 111 patients treated were still living at the 27-month median follow-up.
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
